文献速递乳腺PETMR

同步PET/MRI获得的药代动力学与代谢参数在乳腺癌中的关联:初步发现及对疗效评估的影响

Association of pharmacokinetic and metabolic parameters derived using simultaneous PET/MRI: Initial findings and impact on response evaluation in breast cancer.
PubMed 文献 · Eur J Radiol · 2017-04-23

研究纳入41例乳腺癌患者行同步PET/MRI,分析18F-FDG PET参数与药代动力学参数的相关性,另对9例患者治疗前后评估疗效。SUV与Ktrans、Kep、iAUC呈显著正相关,ve/iAUC比值与SUV呈显著负相关;SUV及药代动力学参数预测疗效的能力在9例患者11个病灶中有9个与RECIST标准一致。

要点

  • SUVmean、SUVmax、SUVpeak、TLG与Ktrans呈显著正相关(ρ=0.446、0.417、0.491、0.430,p≤0.01)。
  • ve/iAUC比值与SUVmean、SUVmax、SUVpeak、TLG呈显著负相关(ρ=0.420、0.446、0.443、0.426,p≤0.01)。
  • SUV及药代动力学参数预测化疗疗效的能力在9例患者11个病灶中有9个与RECIST标准一致。

核心结论

  • 同步PET/MRI可显示乳腺癌患者葡萄糖代谢与药代动力学参数之间的密切相互作用,并提示二者同步获取在疗效评估中具有潜力。

研究设计与样本

  • 研究纳入41例乳腺癌患者进行相关性研究,另纳入9例患者(治疗前后)进行疗效评估,所有患者均接受专用乳腺同步PET/MRI检查,药代动力学参数与PET参数分别使用本院开发软件和厂商提供软件获得。

诊断标准与关键数值

  • SUVmean与Ktrans的相关系数ρ=0.446(p≤0.01),SUVmax与Ktrans的ρ=0.417(p≤0.01),SUVpeak与Ktrans的ρ=0.491(p≤0.01),TLG与Ktrans的ρ=0.430(p≤0.01)。
  • SUVmean、SUVmax、SUVpeak与Kep的相关系数分别为ρ=0.303、ρ=0.315、ρ=0.319(p≤0.05)。
  • SUVmean、SUVmax、SUVpeak与iAUC的相关系数分别为ρ=0.401(p≤0.05)、ρ=0.410(p≤0.05)、ρ=0.379(p≤0.01),TLG与iAUC的ρ=0.379(p≤0.01)。
  • ve/iAUC比值与SUVmean、SUVmax、SUVpeak、TLG的相关系数分别为ρ=0.420、0.446、0.443、0.426(p≤0.01),呈显著负相关。
  • SUV及药代动力学参数预测疗效的能力在9例患者11个病灶中有9个与RECIST标准一致,治疗后定量下降最大者为SUVpeak、TLG和Ktrans。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To study relationships among pharmacokinetic and 18F-fluorodeoxyglucose (18F-FDG) PET parameters obtained through simultaneous PET/MRI in breast cancer patients and evaluate their combined potential for response evaluation.

METHODS: The study included 41 breast cancer patients for correlation study and 9 patients (pre and post therapy) for response evaluation. All patients underwent simultaneous PET/MRI with dedicated breast imaging. Pharmacokinetic parameters and PET parameters for tumor were derived using an in- house developed and vendor provided softwares respectively. Relationships between SUV and pharmacokinetic parameters and clinical as well as histopathologic parameters were evaluated using Spearman correlation analysis. Response to chemotherapy was derived as percentage reduction in size and in parameters post therapy.

RESULTS: Significant correlations were observed between SUVmean, max, peak, TLG with Ktrans (ρ=0.446, 0.417, 0.491, 0.430; p≤0.01); with Kep(ρ=0.303, ρ=0.315, ρ=0.319; p≤0.05); and with iAUC(ρ=0.401, ρ=0.410, ρ=0.379; p≤0.05, p≤0.01). The ratio of ve/iAUC showed significant negative correlation to SUVmean, max, peak and TLG (ρ=0.420, 0.446, 0.443, 0.426; p≤0.01). Ability of SUV as well as pharmacokinetic parameters to predict response to therapy matched the RECIST criteria in 9 out of 11 lesions in 9 patients. Maximum post therapy quantitative reduction was observed in SUVpeak, TLG and Ktrans.

CONCLUSION: Simultaneous PET/MRI enables illustration of close interactions between glucose metabolism and pharmacokinetic parameters in breast cancer patients and potential of their simultaneity in response assessment to therapy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Jena A, Taneja S, Singh A, et al. Association of pharmacokinetic and metabolic parameters derived using simultaneous PET/MRI: Initial findings and impact on response evaluation in breast cancer. Eur J Radiol. 2017. PMID: 28624017. doi:10.1016/j.ejrad.2017.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。